Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Inv. presentation
Avidity Biosciences, Inc. (RNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months"
05/09/2023 8-K Quarterly results
Docs: "Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrated Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1"
02/28/2023 8-K Quarterly results
Docs: "Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights"
11/08/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights Company remains on track to have three programs in the clinic by the end of this year"
05/10/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
Docs: "Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights"
11/09/2021 8-K Quarterly results
Docs: "Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights Initiated the Phase 1/2 MARINA TM trial of AOC 1001, marking the first AOC in clinical development On track to have three clinical programs by the end of 2022"
08/09/2021 8-K Quarterly results
Docs: "Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights"
05/12/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Presented at Key Scientific Meetings. Avidity presented at several key virtual scientific meetings, including TIDES USA 2020, the 16th Annual Meeting of the Oligonucleotide Therapeutics Society 2020, the Next Generation Protein Therapeutics and Bioconjugates Summit 2020, and TIDES Europe 2020. In early December 2020, the company plans to present an overview of its AOC technology and preclinical data at the 3rd Annual Neuromuscular Drug Development Summit. • Entered into Collaboration to Study the Natural History of DM1 to Support Lead Program AOC 1001. Avidity entered into a collaboration supporting END-DM1 , a natural history study to advance the understanding of disease progression in patients with myotonic dystrophy type 1 . This new collaboration supports Avidity’s lead program,..."
08/10/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy